- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
HemoBioTech, Inc. (OTCBB: HMBT) announced today that Arthur Bollon, Ph.D., Chairman and Chief Executive Officer of HemoBioTech, will be presenting at the nanoTX ‘07 Conference and Expo in Dallas, Texas on Wednesday, October 3, 2007 at 10:30AM CST, at the Dallas Convention Center, Venue: A130-131. Dr. Bollon will make a presentation of the company's proprietary HemoTech™ blood substitute technology, recent developments, and commercial strategy.
nanoTX is one of the world’s most comprehensive nanotechnology conferences and exhibitions. The event highlights advances in nanoscience, explains how nanotechnology is being used today and how it will impact a broad range of industries tomorrow, including: biomedicine, electronics, energy, aerospace, defense, robotics, chemicals, and more.
nanoTX ’07 will involve over 150 nanotechnology specialists from 30 different countries and a special Nobel Laureates Legends reception. For more information, please click here http://www.nanotx.biz .
About HemoBioTech, Inc.
HemoBioTech is engaged in the development of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, adenosine, and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities which have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. by prior holders of this technology. HemoTech is being subjected to further studies and testing to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com .
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech’s Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTech’s other reports filed with the Securities and Exchange Commission.
For more information, please click here
Arthur P. Bollon, Ph.D.
Chief Executive Officer
The Investor Relations Group, Inc.
Christine Berni/Joseph Triunfo, 212-825-3210
Janet Vasquez/Michaela Heller, 212-825-3210
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016
IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016
Cutting-edge nanotechnologies are breaking into industries November 18th, 2016